A Phase 2 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Terminated at 51 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 52nd largest by enrollment, is one of 4 that started in 2014, is one of 60 in phase 2, and was the 111th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 119th largest by enrollment of the 155 interventional ones that give a count, is one of 13 that started in 2014, is one of 39 in phase 2, and was the 115th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, open-label, Phase II study in subjects with Human epidermal growth factor receptor (HER2)-positive metastatic breast cancer who received at least 2 prior lines of anti-HER2-targeted therapies of which at least one included a Trastuzumab-containing regimen. This study was a post-approval commitment with regulatory authorities. It was designed to evaluate whether treatment with Dual blockade promoted changes to biomarkers associated with immunomodulation.
This study was designed to address the post-authorization measures as agreed with the Committee for Medicinal Products for Human Use (CHMP). Recruitment of subjects into this study was challenging, and following agreement with the European Medicines Agency (EMA) enrollment into this study was halted after the enrollment of 42 of the 225 planned subjects.
The primary endpoint of the study evaluated changes in expression of biomarkers associated with immunomodulation between a pre-treatment biopsy and the disease progression biopsy. Secondary efficacy endpoints included overall response rate, clinical benefit rate and progression-free survival (PFS), as well as safety/tolerability. All subjects received study treatment until disease progression, death, unacceptable toxicity, or subject withdrawal. In case of disease progression during the treatment period, the subject was followed-up for 30 days for safety evaluation. In case of study treatment discontinuation for any reasons other than disease progression, the subject was followed-up for safety and efficacy assessments until disease progression, new anticancer therapy, death, withdrawal of consent or end of study, whichever came first.
This study supported a better understanding of the rapidly accumulating evidence for the importance of the immune microenvironment in HER2-positive breast cancer and the observed immunomodulation in the neoadjuvant setting could be confirmed in the advanced setting and supported the putative mechanism of action of HER2 dual blockade and its potential function on the tumor microenvironment. No formal comparisons between treatment arms were undertaken.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
Drug: Lapatinib · Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)
In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)
In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
Drug: Lapatinib · Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)
Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
This study also gives Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.
Fold Change in Expression Profile of Genes and/or Proteins for Arm A (LAP+TRAS±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
Time frame: At screening and at disease progression, assessed up to approx. 3.5 years
Fold Change in Expression Profile of Genes and /or Proteins for Arm B (TRAS+CHEM±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
Time frame: At screening and at disease progression, assessed up to approx. 3.5 years
Fold Change in Expression Profile of Genes and /or Proteins for Arm C (Non-HER2- Enriched) From Screening to Approx. 3.5 Years
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
Time frame: At screening and at disease progression, assessed up to approx. 3.5 years
Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization (for Arm A and B) / treatment start date (for Arm C) to the date of the first documented disease progression or death due to any cause, whichever was earlier. If a subject had not progressed or died at the analysis cutoff date, PFS was censored at the time of the last adequate tumor assessment. PFS was summarized using Kaplan-Meier estimates.
Time frame: From randomization to disease progression or death, up to approx. 5.6 years
Overall Response Rate (ORR)
Overall response rate was defined as the percentage of subjects achieving either a confirmed complete response (CR) or partial response (PR) and was calculated from the Investigator's assessment of response per RECIST 1.1 criteria. . The confirmed CR or PR was derived using the following rules: confirmed CR - at least two determinations of CR at least 4 weeks apart before disease progression; confirmed PR - at least two determinations of PR or better at least 4 weeks apart before progression.
Time frame: From enrollment/randomization to the end of study, approximately 5.6 years
Clinical Benefit Rate (CBR)
CBR is defined as percentage of subjects with a complete response (CR), partial response (PR), or maintaining stable disease (SD) for at least 24 weeks while on study according to the investigator assessment of response per RECIST 1.1 criteria. CR and PR are confirmed responses derived using the following rules: Confirmed CR - at least 2 determinations of CR at least 4 weeks apart before disease progression. Confirmed PR - at least 2 determinations of PR or better at least 4 weeks apart before progression.
Time frame: From enrollment/randomization the end of study, approximately 5.6 years
Association Between Biomarkers and PFS
Describe if changes of biomarker expression at disease progression from baseline correlate with PFS.
Time frame: From randomization to disease progression or death, up to approx. 5.6 years
Overall, 225 subjects were planned and 42 subjects were enrolled in this study
| Milestone | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C |
|---|---|---|---|
| Started | 17 | 15 | 10 |
| Total deaths | 11 | 9 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 17 | 15 | 10 |
| Withdrew: Disease progression (incl. death due to disease progression) | 14 | 13 | 8 |
| Withdrew: Adverse event | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Investigator discretion | 0 | 0 | 1 |
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
| Ratio of gene expression level | LAP+TRAS±AI (HER2-Enriched) - Arm A |
|---|---|
| Membrane spanning 4-domains A1 | 0.25 (0.078 to 0.589) |
| POU class 2 associating factor 1 | 0.32 (0.183 to 0.543) |
| CD19+ | 0.35 (0.106 to 0.904) |
| Interleukin 6 | 0.36 (0.033 to 0.832) |
| G antigen 1 | 0.43 (0.030 to 0.901) |
| ubiquitin specific peptidase 9, Y-linked | 0.50 (0.321 to 0.770) |
| Thy-1 cell surface antigen | 0.50 (0.113 to 0.902) |
| Chemerin chemokine-like receptor 1 | 0.51 (0.345 to 0.862) |
| Major histocompatibility complex, class II, DR beta 4 | 0.51 (0.320 to 0.984) |
| Collectin subfamily member 12 | 0.51 (0.151 to 0.794) |
| Complement C3b/C4b receptor 1 (Knops blood group) | 0.51 (0.227 to 0.901) |
| CD33 molecule | 0.56 (0.458 to 0.826) |
| B-cell linker | 0.56 (0.326 to 0.874) |
| Interleukin 12A | 0.57 (0.228 to 0.892) |
| CD163+ | 0.57 (0.417 to 0.911) |
| C-C motif chemokine ligand 8 | 0.58 (0.138 to 0.954) |
| Chemokine (C-C motif) receptor 1 | 0.59 (0.501 to 0.792) |
| POU class 2 homeobox 2 | 0.60 (0.440 to 0.944) |
| Cyclin dependent kinase inhibitor 1A | 0.62 (0.453 to 0.873) |
| CD27 molecule | 0.62 (0.357 to 0.886) |
| Lymphocyte antigen 86 | 0.63 (0.383 to 0.906) |
| TNF superfamily member 8 | 0.64 (0.476 to 0.879) |
| CD34+ | 0.67 (0.558 to 0.863) |
| Integrin subunit alpha 6 | 0.68 (0.470 to 0.827) |
| C-type lectin domain containing 7A | 0.69 (0.326 to 0.944) |
| CD180 molecule | 0.70 (0.347 to 0.869) |
| Integrin subunit alpha M | 0.72 (0.411 to 0.957) |
| Toll like receptor 6 | 0.72 (0.511 to 0.836) |
| Autophagy related 10 | 0.73 (0.662 to 0.864) |
| C-C motif chemokine ligand 3 like 1 | 0.74 (0.499 to 0.996) |
| Bone marrow stromal cell antigen 1 | 0.75 (0.345 to 0.922) |
| CD22+ | 0.76 (0.629 to 0.936) |
| CD37 molecule | 0.76 (0.553 to 0.884) |
| NEG_A | 0.77 (0.674 to 0.949) |
| Sperm auto antigenic protein 17 | 0.79 (0.697 to 0.968) |
| CD200 molecule | 0.79 (0.598 to 0.945) |
| TNF receptor associated factor 3 | 0.82 (0.718 to 0.962) |
| Interferon alpha and beta receptor subunit 1 | 1.10 (1.036 to 1.124) |
| TNF receptor associated factor 6 | 1.21 (1.016 to 1.332) |
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
| Ratio of gene expression level | TRAS+CHEM±AI (HER2-Enriched) - Arm B |
|---|---|
| C-type lectin domain containing 5A | 0.16 (0.020 to 0.440) |
| Interferon induced transmembrane protein 1 | 0.25 (0.183 to 0.421) |
| Fibronectin 1 | 0.27 (0.077 to 0.393) |
| C-C motif chemokine ligand 7 | 0.27 (-0.064 to 0.888) |
| Triggering receptor expressed on myeloid cells 1 | 0.27 (-0.018 to 0.959) |
| Plasminogen activator, urokinase | 0.27 (0.112 to 0.545) |
| Interleukin 22 receptor subunit alpha 2 | 0.28 (0.192 to 0.425) |
| C-C motif chemokine ligand 8 | 0.28 (0.044 to 0.699) |
| Tumor necrosis factor (ligand) superfamily member 4 gene | 0.31 (0.147 to 0.651) |
| Major histocompatibility complex, Class I-related | 0.32 (0.139 to 0.832) |
| Cathepsin L | 0.32 (0.066 to 0.820) |
| SPP-1 (Osteopontin) | 0.33 (0.076 to 0.501) |
| Thy-1 cell surface antigen | 0.34 (0.157 to 0.648) |
| Transforming growth factor beta 2 | 0.35 (0.120 to 0.504) |
| Hepatitis A virus cellular receptor 2 | 0.36 (0.138 to 0.614) |
| Bone marrow stromal cell antigen 1 | 0.37 (0.133 to 0.864) |
| C-type lectin domain containing 7A | 0.37 (0.166 to 0.570) |
| C-X-C motif chemokine ligand 5 | 0.38 (0.040 to 0.943) |
| Collagen type III alpha 1 chain | 0.40 (0.130 to 0.685) |
| Complement C1s | 0.41 (0.088 to 0.717) |
| IFIT1 gene | 0.41 (0.148 to 0.921) |
| Major histocompatibility complex, class I, G | 0.41 (0.147 to 0.698) |
| Tumour necrosis factor gene | 0.42 (0.108 to 0.945) |
| Integrin subunit beta 1 | 0.43 (0.231 to 0.864) |
| Pro-melanin concentrating hormone | 0.43 (0.081 to 0.972) |
| CD86+ | 0.44 (0.102 to 0.700) |
| FCGR3A SNP rs396991 | 0.44 (0.107 to 0.696) |
| TNF receptor superfamily member 10c | 0.44 (0.165 to 0.925) |
| Integrin subunit alpha M | 0.45 (0.166 to 0.797) |
| TNF receptor superfamily member 11b | 0.45 (0.114 to 0.923) |
| Platelet derived growth factor C | 0.45 (0.231 to 0.797) |
| Mannan binding lectin serine peptidase 1 | 0.46 (0.304 to 0.896) |
| Recombination activating 1 | 0.46 (0.394 to 0.597) |
| Interleukin 22 | 0.47 (0.229 to 0.609) |
| Tumor necrosis factor (ligand) superfamily member 13b gene | 0.47 (0.179 to 0.697) |
| BMI1 proto-oncogene, polycomb ring finger | 0.47 (0.322 to 0.735) |
| CXCL10 gene | 0.48 (0.074 to 0.986) |
| Leukocyte immunoglobulin like receptor B1 | 0.48 (0.142 to 0.747) |
| MX1 gene | 0.48 (0.155 to 0.781) |
| Tumor necrosis factor (ligand) superfamily member 11 gene | 0.48 (0.227 to 0.798) |
| Cathepsin S | 0.49 (0.138 to 0.807) |
| Interferon induced transmembrane protein 2 | 0.49 (0.245 to 0.887) |
| LYN proto-oncogene, Src family tyrosine kinase | 0.50 (0.360 to 0.685) |
| Platelet derived growth factor receptor beta | 0.50 (0.160 to 0.801) |
| OAS3 gene | 0.50 (0.284 to 0.899) |
| CD58 molecule | 0.50 (0.398 to 0.619) |
| complement C3a receptor 1 | 0.51 (0.147 to 0.949) |
| Chemokine (C-C motif) receptor 1 | 0.52 (0.159 to 0.815) |
| Interleukin 24 gene | 0.52 (0.161 to 0.706) |
| Chemokine (C-X-C motif) receptor 2 | 0.53 (0.295 to 0.629) |
| Strawberry notch homolog 2 | 1.13 (1.045 to 1.300) |
| Zinc finger protein 205 | 1.42 (1.144 to 1.815) |
| Fas associated via death domain | 1.58 (1.107 to 2.043) |
| CD3e molecule associated protein | 1.67 (1.244 to 2.075) |
| Baculoviral IAP repeat containing 5 | 1.73 (1.003 to 2.635) |
| Interleukin 17 receptor B | 2.01 (1.151 to 2.975) |
Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.
| Ratio of gene expression level | Non-HER2- Enriched - Arm C |
|---|---|
| Triggering receptor expressed on myeloid cells 1 | 0.50 (0.294 to 0.995) |
| Interleukin 1 receptor, type 1 gene | 1.58 (1.235 to 2.328) |
| Complement component 2 | 2.13 (1.011 to 3.567) |
| Coagulation factor XII | 2.69 (1.062 to 4.229) |
PFS was defined as the time from the date of randomization (for Arm A and B) / treatment start date (for Arm C) to the date of the first documented disease progression or death due to any cause, whichever was earlier. If a subject had not progressed or died at the analysis cutoff date, PFS was censored at the time of the last adequate tumor assessment. PFS was summarized using Kaplan-Meier estimates.
| Months | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C |
|---|---|---|---|
| Progression-free Survival (PFS) | 6.0 (2.10 to 10.60) | 7.2 (2.10 to 14.80) | 6.0 (1.60 to 8.30) |
Overall response rate was defined as the percentage of subjects achieving either a confirmed complete response (CR) or partial response (PR) and was calculated from the Investigator's assessment of response per RECIST 1.1 criteria. . The confirmed CR or PR was derived using the following rules: confirmed CR - at least two determinations of CR at least 4 weeks apart before disease progression; confirmed PR - at least two determinations of PR or better at least 4 weeks apart before progression.
| Percentage of participants | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C |
|---|---|---|---|
| Overall Response Rate (ORR) | 35.3 (14.2 to 61.7) | 33.3 (11.8 to 61.6) | 30.0 (6.7 to 65.3) |
CBR is defined as percentage of subjects with a complete response (CR), partial response (PR), or maintaining stable disease (SD) for at least 24 weeks while on study according to the investigator assessment of response per RECIST 1.1 criteria. CR and PR are confirmed responses derived using the following rules: Confirmed CR - at least 2 determinations of CR at least 4 weeks apart before disease progression. Confirmed PR - at least 2 determinations of PR or better at least 4 weeks apart before progression.
| Percentage of participants | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 35.3 (14.2 to 61.7) | 46.7 (21.3 to 73.4) | 30.0 (6.7 to 65.3) |
Describe if changes of biomarker expression at disease progression from baseline correlate with PFS.
No measurements were reported for this outcome.
On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 168 weeks for Lapatinib, (treatment duration ranged from 151 to 164 weeks), 164 weeks for Trastuzumab (treatment duration ranged from 0 to 160 weeks), 168 weeks for Aromatase Inhibitors (treatment duration ranged from 9 to 164 weeks). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 5.6 years.
| Participants | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C |
|---|---|---|---|
| Total Deaths | 11 | 9 | 6 |
| On-treatment deaths | 3 | 1 | 0 |
Collected over On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 168 weeks for lapatinib, for a maximum duration of 164 weeks for trastuzumab and for a maximum duration of 168 weeks for aromatase inhibitors (anastrozole, letrozole and exemestane.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAP+TRAS±AI (HER2-Enriched) - Arm A | 3/17 (17.6%) | 1/17 (5.9%) | 15/17 (88.2%) |
| TRAS+CHEM±AI (HER2-Enriched) • ArmB | 1/15 (6.7%) | 1/15 (6.7%) | 14/15 (93.3%) |
| Non-HER2-Enriched - Arm C | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Event | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) • ArmB | Non-HER2-Enriched - Arm C |
|---|---|---|---|
| SeizureNervous system disorders | 0/17 | 0/15 | 1/10 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/17 | 0/15 | 1/10 |
| Breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 1/15 | 0/10 |
| Cardiac arrestCardiac disorders | 1/17 | 0/15 | 0/10 |
| Escherichia sepsisInfections and infestations | 1/17 | 0/15 | 0/10 |
| SepsisInfections and infestations | 1/17 | 0/15 | 0/10 |
| Urinary tract infectionInfections and infestations | 1/17 | 0/15 | 0/10 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/17 | 0/15 | 0/10 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/17 | 0/15 | 0/10 |
| HypokalaemiaMetabolism and nutrition disorders | 1/17 | 0/15 | 0/10 |
| Event | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) • ArmB | Non-HER2-Enriched - Arm C |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/17 | 1/15 | 6/10 |
| VomitingGastrointestinal disorders | 1/17 | 1/15 | 4/10 |
| NauseaGastrointestinal disorders | 1/17 | 5/15 | 3/10 |
| Alanine aminotransferase increasedInvestigations | 0/17 | 5/15 | 0/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/17 | 5/15 | 0/10 |
| Decreased appetiteMetabolism and nutrition disorders | 2/17 | 0/15 | 3/10 |
| NeutropeniaBlood and lymphatic system disorders | 1/17 | 4/15 | 0/10 |
| AstheniaGeneral disorders | 3/17 | 4/15 | 2/10 |
| ParonychiaInfections and infestations | 4/17 | 0/15 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 2/17 | 3/15 | 2/10 |
Full Analysis Set (FAS): Consisted of all subjects who were randomized to study Arm A or Arm B or assigned to study Arm C, irrespective of whether they actually received study treatment.
| Age, Customized(Participants) | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C | Total |
|---|---|---|---|---|
| < 65 years | 14 | 15 | 6 | 35 |
| >= 65 years | 3 | 0 | 4 | 7 |
| Sex: Female, Male(Participants) | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C | Total |
|---|---|---|---|---|
| Female | 17 | 15 | 10 | 42 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | LAP+TRAS±AI (HER2-Enriched) - Arm A | TRAS+CHEM±AI (HER2-Enriched) - Arm B | Non-HER2- Enriched - Arm C | Total |
|---|---|---|---|---|
| Caucasian | 14 | 11 | 10 | 35 |
| African American | 1 | 2 | 0 | 3 |
| Asian | 1 | 2 | 0 | 3 |
| Native Hawaiian or Pacific Islander | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Oct 2014 to primary completion in Jun 2020, 67 months.
Results were first posted in Sep 2021, 1 year 3 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Trastuzumab